Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	HC3 Chemotherapy	57
Overall Study	STARTED	Blinatumomab	54
Overall Study	Participants Treated	HC3 Chemotherapy	52
Overall Study	Participants Treated	Blinatumomab	54
Overall Study	Participants in the Primary Analysis Population	HC3 Chemotherapy	54
Overall Study	Participants in the Primary Analysis Population	Blinatumomab	54
Overall Study	Participants in the Final Analysis Population	HC3 Chemotherapy	57
Overall Study	Participants in the Final Analysis Population	Blinatumomab	54
Overall Study	COMPLETED	HC3 Chemotherapy	16
Overall Study	COMPLETED	Blinatumomab	33
Overall Study	NOT COMPLETED	HC3 Chemotherapy	41
Overall Study	NOT COMPLETED	Blinatumomab	21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02393859/flow